TMSB10 drives prostate cancer aggressiveness via immune microenvironment regulation.

Mol Med · 2025 · PMC12042486 · PMID 40307738

Europe PMC DOI

hedged sentence

0.1050

closest p · 2.1× alpha

0.1050

boldest claim

The sentences

an increasing trendP = 0.105not close (p > 0.1)

3 E showed, progressive TMSB10 upregulation was observed in benign, HSPC, and CRPC groups ( GSE70770 , P < 0.001) and showed an increasing trend post-ADT treatment ( GSE150368 , P = 0.105).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.